Bliss GVS Pharma
BLISSGVS · Pharma > Pharmaceuticals & Drugs · Chairman: S R Vaidya · MD: Gagan Harsh Sharma · Listing date: July 26, 2010 · Employees: 683 · Mumbai · http://www.blissgvs.com

Stock Price vs Company Growth
1d
2.7%
1w
9.7%
1m
1.7%
3m
7.7%
6m
3.5%
1y
11.6%
5y
5.8%
10y
0.8%
all
8.6%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowSep07Mar11Sep14Mar18Sep21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

122 2.7%
105
145
Company Overview

Sales
810 Cr
Growth: 5.4%
Profit after Tax
84.3 Cr
Growth: 41.4%
Small Cap
1,287 Cr
P/E: 15.4x
Industry P/E: 32.3x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 810
Growth 5.4%
EBITDA 15.6%
P/S 1.6x
Dividend 0.4%
P/E 15.4x
Book Value ₹ 99.7
PEG Ratio 2.9x
ROE 8.3%
P/B 1.2x
Shareholding Pattern

Institutions
Arian Investment Ltd
9.7 %
Life Insurance Corporation Of India
6.68 %
Polus Global Fund
4.62 %
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund
2.9 %
Aspire Emerging Fund
2.46 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Promoters
Narsimha Shibroor Kamath
33.24 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Others
Gulbarga Trading And Investment Pvt. Ltd.
5.67 %
Arjun Gautam Ashra
4.89 %
Gautam Rasiklal Ashra
2.82 %
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs
2.2 %
Llp
0.05 %
Created with Highcharts 8.2.2Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Increase    Decrease    No change
Company Profile Detailed

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception.
Investors (60)
Followers (10)